In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease

Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy

(2018) Maria J. Casarejos et al.   JOURNAL OF ALZHEIMERS DISEASE

The Role of Endocannabinoid Signaling in the Molecular Mechanisms of Neurodegeneration in Alzheimer's Disease

(2018) Gaurav Bedse et al.   JOURNAL OF ALZHEIMERS DISEASE

Cannabis-Based Medicine Reduces Multiple Pathological Processes in AβPP/PS1 Mice

(2018) Ester Aso et al.   JOURNAL OF ALZHEIMERS DISEASE

Long-Term Cannabidiol Treatment Prevents the Development of Social Recognition Memory Deficits in Alzheimer's Disease Transgenic Mice

(2018) David Cheng et al.   JOURNAL OF ALZHEIMERS DISEASE

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

2015 Alzheimer's disease facts and figures

(2015)   Alzheimers & Dementia

Cannabinoids in late-onset Alzheimer's disease

(2015) AIA Ahmed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Endocannabinoid signalling and the deteriorating brain

(2015) Vincenzo Di Marzo et al.   NATURE REVIEWS NEUROSCIENCE

Immunotherapy for Alzheimer's disease

(2014) Thomas Wisniewski et al.   BIOCHEMICAL PHARMACOLOGY

Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice

(2014) David Cheng et al.   PSYCHOPHARMACOLOGY

Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic

(2014) Ester Aso et al.   Frontiers in Pharmacology

Cannabinoid Effects on β Amyloid Fibril and Aggregate Formation, Neuronal and Microglial-Activated Neurotoxicity In Vitro

(2013) Emelie Janefjord et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Cannabidiol Promotes Amyloid Precursor Protein Ubiquitination and Reduction of Beta Amyloid Expression in SHSY5YAPP+Cells Through PPARγ Involvement

(2013) Caterina Scuderi et al.   PHYTOTHERAPY RESEARCH

Treatment Strategies Targeting Amyloid  -Protein

(2013) D. Schenk et al.   Cold Spring Harbor Perspectives in Medicine

Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?

(2012) Kevin Mullane et al.   BIOCHEMICAL PHARMACOLOGY

Genetic insights in Alzheimer's disease

(2012) Karolien Bettens et al.   LANCET NEUROLOGY

Contrasting protective effects of cannabinoids against oxidative stress and amyloid-β evoked neurotoxicity in vitro

(2012) Benjamin S. Harvey et al.   NEUROTOXICOLOGY

The endocannabinoid system in normal and pathological brain ageing

(2012) A. Bilkei-Gorzo   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs

(2011) Salvatore Salomone et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

γ-Secretase Inhibitors and Modulators for the Treatment of Alzheimer's Disease: Disappointments and Hopes

(2011) Bruno P. Imbimbo et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Memantine in dementia: a review of the current evidence

(2011) Nathan Herrmann et al.   EXPERT OPINION ON PHARMACOTHERAPY

Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death

(2011) Partha Mukhopadhyay et al.   FREE RADICAL BIOLOGY AND MEDICINE

Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease

(2011) A. M. Martin-Moreno et al.   MOLECULAR PHARMACOLOGY

Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ Involvement

(2011) Giuseppe Esposito et al.   PLoS One

Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats

(2011) Charlotte Klein et al.   PSYCHOPHARMACOLOGY

The cholinergic system in aging and neuronal degeneration

(2010) Reinhard Schliebs et al.   BEHAVIOURAL BRAIN RESEARCH

N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor

(2010) Douglas McHugh et al.   BMC NEUROSCIENCE

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

The Role of Neuroimmunomodulation in Alzheimer's Disease

(2009) Ricardo B. Maccioni et al.   Annals of the New York Academy of Sciences

Animal models of Alzheimer's disease and frontotemporal dementia

(2008) Jürgen Götz et al.   NATURE REVIEWS NEUROSCIENCE

Neuroinflammation: Implications for the Pathogenesis and Molecular Diagnosis of Alzheimer's Disease

(2007) Leonel E. Rojo et al.   ARCHIVES OF MEDICAL RESEARCH

The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin

(2007) R G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

The orphan receptor GPR55 is a novel cannabinoid receptor

(2007) E Ryberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression

(2007) G Esposito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY